BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 549 filers reported holding BIO-TECHNE CORP in Q1 2022. The put-call ratio across all filers is 0.27 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2021 | $618,000 | +67.0% | 1,194 | +56.5% | 0.17% | +49.1% |
Q3 2021 | $370,000 | +7.6% | 763 | 0.0% | 0.11% | +10.9% |
Q2 2021 | $344,000 | +18.2% | 763 | 0.0% | 0.10% | +11.0% |
Q1 2021 | $291,000 | +20.2% | 763 | 0.0% | 0.09% | +21.3% |
Q4 2020 | $242,000 | +15.2% | 763 | -9.9% | 0.08% | +4.2% |
Q3 2020 | $210,000 | -0.9% | 847 | 0.0% | 0.07% | -7.7% |
Q2 2020 | $212,000 | +39.5% | 847 | +5.9% | 0.08% | +16.4% |
Q1 2020 | $152,000 | -16.9% | 800 | -4.2% | 0.07% | 0.0% |
Q4 2019 | $183,000 | +12.3% | 835 | 0.0% | 0.07% | +8.1% |
Q3 2019 | $163,000 | -10.4% | 835 | -4.1% | 0.06% | -11.4% |
Q2 2019 | $182,000 | +5.2% | 871 | 0.0% | 0.07% | +4.5% |
Q1 2019 | $173,000 | +21.0% | 871 | -11.6% | 0.07% | +8.1% |
Q4 2018 | $143,000 | -23.9% | 985 | +6.8% | 0.06% | -8.8% |
Q3 2018 | $188,000 | +38.2% | 922 | 0.0% | 0.07% | +36.0% |
Q2 2018 | $136,000 | +3300.0% | 922 | +3741.7% | 0.05% | +4900.0% |
Q1 2018 | $4,000 | +33.3% | 24 | 0.0% | 0.00% | 0.0% |
Q4 2017 | $3,000 | 0.0% | 24 | 0.0% | 0.00% | 0.0% |
Q3 2017 | $3,000 | – | 24 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Broadcrest Asset Management, LLC | 300,000 | $24,489,000 | 21.05% |
Montanaro Asset Management Ltd | 388,800 | $31,737,744 | 5.02% |
Sandhill Capital Partners LLC | 502,447 | $41,014,775 | 3.74% |
Brown Capital Management | 3,160,892 | $258,023,614 | 3.66% |
DF DENT & CO INC | 3,275,617 | $267,388,640 | 3.62% |
Ownership Capital B.V. | 2,282,104 | $186,288,150 | 3.26% |
Jackson Square Partners, LLC | 1,361,789 | $111,162,836 | 3.24% |
STONE RUN CAPITAL, LLC | 88,135 | $7,194,460 | 3.20% |
Pembroke Management, LTD | 339,591 | $27,720,813 | 2.99% |
Summit Creek Advisors LLC | 283,693 | $23,157,860 | 2.90% |